Powerful Medical Receives €40 Million IPCEI Grant — read the full story

Powerful Medical
13. January 2025
3 min to read

Artificial Intelligence–Powered Electrocardiogram Detecting Culprit Vessel Blood Flow Abnormality: AI-ECG TIMI Study Design and Rationale

Overview

The AI-ECG TIMI study is a unique, multicenter registry currently enrolling patients to evaluate an AI-powered ECG model for detecting actively obstructed arteries in acute coronary syndrome (ACS). It is the first study to collect standard 12-lead ECGs precisely at the time of coronary angiography, providing novel insights into coronary occlusion and reperfusion. By identifying high-risk ECG patterns and assessing AI’s role in predicting intervention success, it paves the way for AI-driven precision cardiology in acute care.

Study DesignProspective Observational Study
StatusEnrolling patients
Countries / Sites3 (BE, IT, AT) / 9
Study StartDecember 24, 2024
Primary Completion (Estimated)July 1, 2025
Enrollment (target)709
clinicaltrials.gov IDNCT06528821

Study Design and Rationale:

Published In: Journal of the Society for Cardiovascular Angiography & Interventions (JSCAI) in their special issue on Role of AI in Cardiovascular Interventions

Date of Publication: January 13, 2025

Background

The 12-lead electrocardiogram (ECG) is the gold standard for detecting patients who will benefit from emergent revascularization due to occlusive myocardial infarction (OMI). However, the pathophysiology of acute coronary syndromes (ACS) is dynamic, and nearly half of patients with OMI do not present with typical ST elevation or have dynamic ECG changes due to spontaneous recanalization before invasive coronary angiography (ICA). Recently, an ECG-based artificial intelligence (AI) model was developed using expert interpretation of OMI. However, its performance is limited to retrospective evaluation of ECGs recorded minutes to hours before ICA.

Methods

The AI-ECG thrombolysis in myocardial infarction (TIMI) study is an investigator-initiated prospective multicenter registry planning to enroll over 700 consecutive patients with ACS undergoing ICA in 9 centers across Europe. For all participants, a standard 10-second 12-lead ECG will be recorded at the time of coronary angiography. The primary end point is the AI model’s ability to identify patients with an actively occluded (TIMI 0-1) culprit coronary artery at the time of invasive coronary angiography using only single-standard 12-lead ECGs. Standardized angiograms will be used as a reference standard.

Conclusion

AI-ECG TIMI is the first prospective registry of consecutive patients with ACS with standard 12-lead ECGs recorded at the very moment of ICA. This study will help characterize ECG findings of abnormal myocardial perfusion due to acute active ischemia and prospectively validate an AI model’s ability to detect them.

Authors: Robert Herman MD, PhD, Timea Kisova MD, Marta Belmonte MD, Adriaan Wilgenhof MD, Gabor Toth MD, PhD, Anthony Demolder MD, PhD, Adam Rafajdus MSc, H. Pendell Meyers MD, Stephen W. Smith MD, Jozef Bartunek MD, PhD, Emanuele Barbato MD, PhD

Author-Logo_PM
Powerful Medical leads one of the most important shifts in modern medicine by augmenting human-made clinical decisions with artificial intelligence. Our primary focus is on cardiovascular diseases, the world’s leading cause of death.

About PMcardio

PMcardio is a CE-certified AI that reads ECGs and offers a complex assessment of 49 cardiac conditions. Clinically validated in 15+ studies and trusted by over 100,000 clinicians, it delivers rapid, expert‑level interpretations, empowering emergency physicians, GPs, nurses, paramedics, and cardiologists to act with confidence at the point of care. Available for Individuals and Organizations.

About Powerful Medical

Established in 2017, Powerful Medical has embarked on a mission to revolutionize the diagnosis and treatment of cardiovascular diseases. We are a medical company backed by 28 world-class cardiologists and led by our expert Scientific Board with decades of experience in daily patient care, clinical research, and medical devices. The results of our research are implemented, developed, certified, and brought to market by our 50+ strong interdisciplinary team of physicians, data scientists, AI experts, software engineers, regulatory specialists, and commercial teams.

Share this article

Relevant Publications

Occlusion myocardial infarction: a revolution in acutecoronary syndrome

The 2025 ACC Guideline for the Management of Patients With Acute Coronary Syndromes claims that “Patients with NSTEMI may have a partially occluded coronary artery leading to subendocardial ischemia, while those with STEMI typically have a completely occluded vessel leading to transmural myocardial ischemia and infarction.” This is accompanied by a visual representation of a partially occlusive thrombus labeled ‘NSTEMI’ above an electrocardiogram (ECG) showing ST depression and T wave inversion, and a completely occlusive thrombus labeled ‘STEMI’ above an ECG showing ST elevation. This paradigm has remained despite two decades of angiographic and evidence-based ECG advances, which highlight the multiple reasons why a revolution in acute coronary syndrome (ACS) is needed, and has begun.

Accuracy of cath lab activation decisions for STEMI-equivalent and mimic ECGs: Physicians vs. AI (PMcardio, queen of hearts)

This study aimed to measure physician accuracy for interpreting STEMI-equivalent and STEMI-mimic ECGs for catheterization laboratory activation (CLA) and compare their performance to a machine learning-based artificial intelligence algorithm, Queen of Hearts AI (QoH AI).

Join over 100,000 healthcare professionals who are already taking advantage of AI